A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

September 10, 2021

Study Completion Date

August 9, 2022

Conditions

Advanced Solid Tumors

Interventions

DRUG

IBI310

IBI310 is anti CTLA-4 antibody

DRUG

Sintilimab

PD-1 monoclonal antibody

Trial Locations (1)

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter